Xinyu (Annie) Li advises life sciences and technology companies on a wide range of corporate and transactional matters, with particular experience in licensing, collaboration, supply, manufacturing, and other commercial agreements that support research, development, and commercialization. She regularly assists clients in structuring and negotiating agreements that are critical to advancing scientific programs and business objectives, including transactions with international counterparties.
Her practice also includes representing emerging companies and investors in venture capital financings in various stages. She has experience advising on cross-border financings and investments, supporting both U.S. companies receiving international capital and foreign companies entering the U.S. market. She assists clients with corporate formation, equity financings, and general governance matters, and works closely with founders, management teams, and investors to help execute growth strategies.
Experience
- Transaction team member to AprilBio Co., Ltd. (Kosdaq: 397030) in its exclusive, worldwide license agreement with Evommune, Inc. to develop and commercialize a Phase 2-ready IL-18 targeted fusion protein for the regulation of inflammation. AprilBio is eligible for up to $475 million plus royalties in total consideration.
- Transaction team member to AcuraStem, a California biotech, in connection with its exclusive, worldwide license agreement with Takeda for its PIKFYVE program. If the agreed upon clinical, regulatory, and commercial milestones are met, AcuraStem will receive a total of US$580 million from Takeda in upfront and milestone payments. AcuraStem will also receive tiered royalties on any net sales.*
- Leading horizontal platform for cell programming, in its acquisition of adeno-associated virus (AAV) capsid discovery and engineering platform assets.*
- Biotechnology company in an agreement with a synthetic biology company developing new sustainable bio-based ingredients, in a multi-stage partnership focused on compounds in the tryptophan pathway.*
- Biotechnology company developing new ways to treat neurological disorders in its Series A financing.*
*Reflects experience at previous employer.
Credentials
Education
- J.D., Boston University School of Law, 2020
- B.A., Brandeis University, 2017, summa cum laude, Phi Beta Kappa
Admissions
- Massachusetts
Activities
- Member, Asian American Lawyers Association of Massachusetts
Languages
- Chinese (Mandarin)